Skip to content
Menu
GHK-Cu Safe

GHK-Cu safety questions, answered only from peer-reviewed work.

GHK-Cu references

Each source below has a specific role. The notes identify who published the work, when it appeared, and what kind of question it can help answer. They also keep regulatory records separate from journal evidence.

Skin and pigment studies

Maquart and colleagues, 1988

Fibroblasts in culture made more collagen after exposure to GHK-Cu. This is an early laboratory finding about cell activity, with no measurement of visible skin changes in people.

Simeon and colleagues, 2000

A cell experiment examined MMP-2, an enzyme involved in remodeling the material around cells. Copper-bound GHK and free GHK did not produce the same response.

Pickart, Vasquez-Soltero, and Margolina, 2015

This review connects skin-cell experiments with reports of topical cosmetic studies. Some much-cited human findings lead back to conference material, a report, or a book chapter rather than full journal trial reports.

Mortazavi and colleagues, 2025

A review of topical GHK research considers wrinkle-related findings alongside the difficulty of delivering the peptide through skin. It is useful for understanding why the complete formulation belongs in any account of a result.

Miller and colleagues, 2006

Thirteen people took part in a study of copper-peptide skincare after carbon dioxide laser resurfacing. Objective outcomes and participant satisfaction gave different answers, making the choice of outcome particularly important.

Hong and colleagues, 2025

A palmitoyl copper peptide combined with acetyl tyrosine increased melanin-related responses in human and mouse melanoma cell lines. The modified peptide, additional ingredient, and cell model all limit conclusions about ordinary skincare.

Hostynek, Dreher, and Maibach, 2011

An experiment using excised human skin measured the movement and retention of copper after a copper-tripeptide preparation was applied. It measured copper, rather than proving that intact GHK-Cu reached the bloodstream.

Hair, delivery, and exposure

Lee and colleagues, 2016

A six-month trial in 45 men studied a topical combination of free GHK and 5-aminolevulinic acid. Hair counts improved relative to the comparison lotion, while hair thickness did not show the same result.

Pyo and colleagues, 2007

Isolated human hair follicles and cultured cells were exposed to AHK-Cu, a related copper peptide. The work supports investigation of that preparation; it is not a trial of GHK-Cu on a person’s scalp.

Liu and colleagues, 2024

A topical delivery experiment included GHK-Cu in a microemulsion and examined hair-related outcomes in mice. Its animal model and specialized carrier remain part of the finding.

Endo, Miyagi, and Ujiie, 1997

A rat plasma study followed free GHK and its breakdown product after intravenous administration. The peptide and species differ from the human copper-complex question often attached to this paper.

Dymek and colleagues, 2023

Laboratory work examined small lipid carriers for GHK-Cu and responses in cultured epidermal cells. Formulation stability and cell findings do not establish clinical effectiveness or a human dosing schedule.

Molavi and colleagues, 2020

A coated scaffold containing GHK-Cu was tested with human dermal fibroblasts and in antibacterial experiments. The results describe the composite material under laboratory conditions, rather than a finished wound treatment.

Pickart and Margolina, 2018

A review discusses gene-expression patterns and repair-related mechanisms associated with GHK. Changes in gene activity provide research leads, but cannot establish longer life or broad rejuvenation in people.

Regulatory records

FDA safety-risk page, content current April 22, 2026

The injectable GHK-Cu entry appears among withdrawn nominations and retains a warning about potential immune reactions, aggregation, impurities, and limited human data. This is a regulatory record, separate from the peer-reviewed studies.

FDA 503A category list, updated May 14, 2026

The list treats GHK-Cu for non-injectable routes separately from the injectable entry. Its under-evaluation category describes a conditional enforcement policy; it does not amount to drug approval.

Following a claim back to its source

The links on guide pages describe the finding or question they support. A review can introduce several experiments, but its summary remains different from an original trial report. When a preparation contains more than one active ingredient, the result belongs to that tested combination unless the experiment separates their contributions.

Publication in a journal does not remove the limits of a small sample, a cell model, or a short observation period. These notes are a reading aid; the source itself supplies the methods and full context needed to assess a particular claim.